The consensus price target hints at a 95.6% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Zai Lab in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen forecasts that the ...

The FDA has granted orphan drug designation (ODD) to Zai Lab’s ZL-1310, aimed at treating small cell lung cancer (SCLC).

Zai Lab Limited (ZLAB) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation or ODD to ZL-1310, a ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan ...

While the stock market in the United States remained closed on January 20 for Martin Luther King, Jr. Day, the day was ...

Chinese regulators have accepted Zai Lab's (NASDAQ:ZLAB) market application for the drug KarXT, also known as xanomeline and ...

Zai Lab (ZLAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Li from Bank of ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the treatment of ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

Zai Lab (ZLAB) stock rose after positive trial data for its cervical cancer drug Tivdak and its plans to seek marketing ...

Zai Lab Limited (NASDAQ:ZLAB) and argenx (Nasdaq: ARGX) today announced that China’s National Medical Products Administration (NMPA) approved the supplemental Biologics License... ByInvesting ...